We like to make our webinars interactive and after our recent webinar on ‘EU MDR’s Impact on Labeling: UDI in Europe and Other Changes’, I thought it would be great to highlight the top five challenges and questions we saw strong responses to
The idea of color printing labels on demand has been thrown around the medical device and pharmaceutical market for many years but in reality, most organizations rely on the traditional two-stage color label printing process they know – batch print and over print. But here lays the problem, huge amounts of label stock on the shelf can be costly and quite often wasted.
The clinical trial market is not only global, today it touches more markets than ever before. Increasingly, a key component of this is the need to comply with variable local language labeling requirements, not least in the safe distribution of medicines for clinical trials. With the global map for clinical studies now extensive, information to support the safe and effectual use of trial medicines must be coherent and understandable to the patients receiving them.
The importance of labeling in clinical trials gets very little exposure. However, as the global war for patients intensifies in an increasingly competitive trial market, and with subject attrition rates commonly shown to be between 15-20%, pharmaceutical companies are slowly discovering that the packaging of their products can be a key determinant of patient retention.
During our recent webinar ‘Future proofing your Clinical Supply Chain’, co-presented by myself and Jason James, Senior Manager, Labelling & Innovation, Bristol-Myers Squibb, we discussed some of the drivers for change in Clinical Research today as well as the impact of these changes on clinical trial supply chain, particularly packaging and labeling operations.